Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
- PMID: 31280968
- DOI: 10.1016/S0140-6736(19)31513-2
Interleukin-23 blockade: another breakthrough in the treatment of psoriasis
Comment on
-
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Lancet. 2019. PMID: 31280967 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical